ALAMEDA, Calif., July 1, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the second quarter 2025 after market close on Tuesday, July 29, 2025 at 4:30 PM Eastern Time. A press release with second quarter 2025 financial results will be issued after market close that day.Webcast & Conference Call InformationThe conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcas ...

STORM-PE is a first-of-its-kind clinical trial comparing computer assisted vacuum thrombectomy (CAVT™) using Penumbra's Lightning Flash™ with anticoagulation versus anticoagulation alone in the treatment of acute intermediate-high risk pulmonary embolismALAMEDA, Calif., June 16, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced the completion of enrollment in the STORM-PE clinical trial. The pivotal, prospective, multi-center randomized controlled trial enr ...

Penumbra’s (PEN) shares have registered impressive momentum in the past year, with shares rallying 35.9%. It has outperformed the industry’s 13.3% decline. However, the S&P 500 composite has gained 11.6% during the same period.Carrying a Zacks Rank #3 (Hold) at present, the renowned thrombectomy company benefits from the strong customer uptake of its Lightning Bolt and Flash lines in both the U.S. and international markets. Penumbra’s overseas operations show strong potential for growth and profit improveme ...

Summary of Penumbra (PEN) 2025 Conference Call Company Overview - **Company**: Penumbra, Inc. (PEN) - **Market Cap**: Increased from $1 billion to approximately $11.12 billion over the past decade [3][4] Core Industry Insights - **Industry**: Medical Devices, specifically focusing on thrombectomy and stroke treatment - **Market Dynamics**: The competitive landscape has evolved, with Penumbra transitioning from competing against other companies to focusing on internal innovation [5][6][15] Key Points and Arguments 1. **Innovation as a Growth Driver**: Penumbra attributes its success to continuous innovation and improvement of its products, particularly in thrombectomy technology [4][5] 2. **Digital Transformation**: The company is entering a digital age, enhancing its product capabilities through software improvements rather than solely hardware changes [6][10] 3. **Market Leadership**: Penumbra remains a dominant player in the aspiration thrombectomy market, despite increased competition from private companies [15][16] 4. **Challenges in Stroke Treatment**: Structural issues in the healthcare system hinder patient access to treatment, impacting growth in the stroke market [17][18] 5. **Regulatory Process**: The company is currently in the FDA review process for its Thunderbolt product, with no significant updates on the timeline for approval [22][23] 6. **Market Access Strategy**: Penumbra is working on demonstrating the clinical and economic benefits of its products to hospitals, aiming to change treatment protocols [50][51][52] 7. **Growth in VTE Market**: The company has seen a 42% growth rate in the US venous thromboembolism (USVT) market, driven by peer recommendations among physicians [43][48] 8. **China Market Impact**: Revenue from China has significantly decreased, impacting overall guidance, but the company remains optimistic about future opportunities [65][67] Additional Important Insights - **Quality of Life Measures**: The company emphasizes the importance of quality of life in its clinical trials, particularly for patients undergoing treatment for intermediate pulmonary embolism [59][61] - **Product Launches**: Excitement around new product launches, such as Ruby XL, indicates ongoing innovation and market engagement [68][69] - **Economic Considerations**: The economic benefits of using Penumbra's products over traditional treatments are highlighted, suggesting a potential shift in hospital protocols [52][53] This summary encapsulates the key insights and strategic directions discussed during the conference call, reflecting Penumbra's focus on innovation, market dynamics, and growth opportunities in the medical device industry.

Company Overview - Penumbra, Inc. is the world's leading thrombectomy company focused on developing innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism, and acute limb ischemia [2] - The company's portfolio includes computer assisted vacuum thrombectomy (CAVT), aimed at removing blood clots efficiently and safely [2] - Penumbra supports healthcare providers in over 100 countries, working to improve patient outcomes and quality of life [2] Upcoming Event - Penumbra's management team is scheduled to present at the BofA Securities 2025 Health Care Conference on May 13, 2025, at 6:00 PM ET [1] - A webcast of the presentation will be available on the company's website for at least two weeks following the event [1]

Penumbra, Inc. (NYSE:PEN) Q4 2024 Earnings Conference Call February 18, 2025 4:30 PM ET Company Participants Cecilia Furlong - Director of Business Development and Investor Relations Adam Elsesser - Chairman & Chief Executive Officer Maggie Yuen - Chief Financial Officer Jason Mills - Executive Vice President of Strategy Conference Call Participants Larry Biegelsen - Wells Fargo Securities Robert Marcus - JPMorgan Pito Chickering - Deutsche Bank Bill Plovanic - Canaccord Richard Newitter - Truist Securities ...